Osteoarthritis Clinical Trials

Find Osteoarthritis Clinical Trials Near You

Evaluation of the Effect of Agar and/or Collagen Based Compounds on Osteoarticular Pain. A Randomized, Parallel, Placebo Controlled, Triple Blind Clinical Trial (AGARTROSIS)

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Joints-comprising bone, cartilage, ligaments, and synovial fluid-enable stable daily movement but may deteriorate with age, excess body weight, overuse, injury, or disease. Such degeneration, common from age 40 onward, underlies joint disorders like osteoarthritis, particularly in the knees, hips, hands, and spine, and is a major cause of chronic pain and disability. While antiinflammatory analgesics remain the standard approach to symptom control, they neither cure disease nor regenerate cartilage and can produce significant long-term adverse effects (gastrointestinal, hepatic, renal, and cardiovascular). These limitations motivate interest in natural or complementary strategies with safer profiles. Within this context, marine algae, especially agar derived from red seaweed, have attracted attention for potential intestinal, metabolic, and joint benefits, aided by their fiber content. Another promising option is undenatured type II collagen (UC-II), the principal structural component of articular cartilage, whose endogenous production declines with age; clinical studies indicate that a daily intake of 40 mg UC-II can improve mobility, reduce pain, and enhance quality of life in individuals with osteoarthritis or exercise-related joint discomfort. Based on these considerations, an agar-agar supplement has been developed to relieve knee joint symptoms.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 70
Healthy Volunteers: f
View:

• Men and women between 40 and 70 years of age.

• Submit a score of 6 to 10 out of 20 on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) knee pain questionnaire.

• Sign the informed consent form.

• Know how to read, write, and speak Spanish and/or Catalan.

Locations
Other Locations
Spain
Eurecat, Technological Center of Catalonia, Nutrition and Health Unit
RECRUITING
Reus
Contact Information
Primary
Antoni Caimari Palou, PhD
antoni.caimari@eurecat.org
0034 977 300 805
Backup
Anna Crescenti, PhD
anna.crescenti@eurecat.org
0034 977 300 431
Time Frame
Start Date: 2025-11-10
Estimated Completion Date: 2027-02
Participants
Target number of participants: 80
Treatments
Experimental: Agar-Agar (A-A)
Participants assigned to this group will receive agar-agar (A-A) supplementation and will take it for 12 weeks.
Experimental: Agar-Agar + undenatured collagen type II (A+UC-II)
Participants assigned to this group will receive agar-agar and undenatured collagen type II (A+UC-II) supplementation and will take it for 12 weeks.
Active_comparator: undenatured collagen type II (UC-II)
Participants assigned to this group will receive undenatured collagen type II (UC-II) supplementation and will take it for 12 weeks.
Placebo_comparator: Placebo
Participants assigned to this group will receive the placebo and will take it for 12 weeks.
Related Therapeutic Areas
Sponsors
Leads: Fundació Eurecat
Collaborators: HISPANAGAR SA

This content was sourced from clinicaltrials.gov